http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 06 Aug 2026 10:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Edgewise+Therapeutics%2C+++++++++++++++++Filed+by%3A+FMR+LLC/26881091.html si-local-file:///var/storage/secattach/20260806/26881091.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Edgewise+Therapeutics%2C+++++++++++++++++Filed+by%3A+FMR+LLC/26881091.html Thu, 06 Aug 2026 10:20:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Edgewise+Therapeutics%2C+++++++++++++++++Filed+by%3A+FMR+LLC/26881091.html si-local-file:///var/storage/secattach/20260806/26881091.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Edgewise+Therapeutics%2C+++++++++++++++++Filed+by%3A+FMR+LLC/26881091.html Thu, 06 Aug 2026 10:20:00 -0400 EWTX O.34381710 http://www.streetinsider.com/Earnings/Edgewise+Therapeutics%2C+Inc.+%28EWTX%29+Misses+Q2+EPS+by+6c/26879425.html <p>Edgewise Therapeutics, Inc. (NASDAQ: EWTX) reported Q2 EPS of ($0.53), $0.06 worse than the analyst estimate of ($0.47). </p><p>For earnings history and earnings-related data on Edgewise Therapeutics, Inc. (EWTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=EWTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Edgewise+Therapeutics%2C+Inc.+%28EWTX%29+Misses+Q2+EPS+by+6c/26879425.html Thu, 06 Aug 2026 08:09:10 -0400 EWTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Edgewise+Therapeutics%2C++++For%3A+Jun+30/26879385.html si-local-file:///var/storage/secattach/20260806/26879385.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Edgewise+Therapeutics%2C++++For%3A+Jun+30/26879385.html Thu, 06 Aug 2026 08:06:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Edgewise+Therapeutics%2C++++For%3A+Jun+30/26879385.html si-local-file:///var/storage/secattach/20260806/26879385.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Edgewise+Therapeutics%2C++++For%3A+Jun+30/26879385.html Thu, 06 Aug 2026 08:06:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+06/26879372.html si-local-file:///var/storage/secattach/20260806/26879372.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+06/26879372.html Thu, 06 Aug 2026 08:05:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+06/26879372.html si-local-file:///var/storage/secattach/20260806/26879372.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Edgewise+Therapeutics%2C++++For%3A+Aug+06/26879372.html Thu, 06 Aug 2026 08:05:00 -0400 EWTX O.34381710 http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26879127.html <div class="xn-content"> <p class="prntac"><i>–</i>  <i>Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p class="prntac"><i>–</i>  <i>Completed sale of sevasemten and muscular dystrophy business to Servier for up to <money>$2.65 billion</money> in <chron>July 2026</chron>, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights<b>.</b></p> <div class="PRN_ImbeddedAssetReference" http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26879127.html Thu, 06 Aug 2026 08:00:00 -0400 EWTX O.34381710 http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26879127.html <div class="xn-content"> <p class="prntac"><i>–</i>  <i>Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p class="prntac"><i>–</i>  <i>Completed sale of sevasemten and muscular dystrophy business to Servier for up to <money>$2.65 billion</money> in <chron>July 2026</chron>, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights<b>.</b></p> <div class="PRN_ImbeddedAssetReference" http://www.streetinsider.com/Press+Releases/Edgewise+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26879127.html Thu, 06 Aug 2026 08:00:00 -0400 EWTX O.34381710 http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26879127.html <div class="xn-content"> <p class="prntac"><i>–</i>  <i>Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p class="prntac"><i>–</i>  <i>Completed sale of sevasemten and muscular dystrophy business to Servier for up to <money>$2.65 billion</money> in <chron>July 2026</chron>, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights<b>.</b></p> <div class="PRN_ImbeddedAssetReference" http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26879127.html Thu, 06 Aug 2026 08:00:00 -0400 EWTX O.34381710 http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26879127.html <div class="xn-content"> <p class="prntac"><i>–</i>  <i>Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –</i></p><p class="prntac"><i>–</i>  <i>Completed sale of sevasemten and muscular dystrophy business to Servier for up to <money>$2.65 billion</money> in <chron>July 2026</chron>, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline –</i></p><p><span class="legendSpanClass"><location value="LU/us.co.bouldr" idsrc="xmltag.org" >BOULDER, Colo.</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EWTX" idsrc="xmltag.org" >Edgewise Therapeutics, Inc.</span> (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights<b>.</b></p> <div class="PRN_ImbeddedAssetReference" http://www.streetinsider.com/PRNewswire/Edgewise+Therapeutics+Reports+Second+Quarter+2026+Financial+Results/26879127.html Thu, 06 Aug 2026 08:00:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edgewise+Therapeutics%2C++++For%3A+Jun+05++Filed+by%3A+ROOT+JONATHAN+D/26784665.html si-local-file:///var/storage/secattach/20260717/26784665.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edgewise+Therapeutics%2C++++For%3A+Jun+05++Filed+by%3A+ROOT+JONATHAN+D/26784665.html Fri, 17 Jul 2026 16:25:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edgewise+Therapeutics%2C++++For%3A+Jun+05++Filed+by%3A+ROOT+JONATHAN+D/26784665.html si-local-file:///var/storage/secattach/20260717/26784665.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Edgewise+Therapeutics%2C++++For%3A+Jun+05++Filed+by%3A+ROOT+JONATHAN+D/26784665.html Fri, 17 Jul 2026 16:25:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Edgewise+Therapeutics%2C++++For%3A+Jul+10/26776961.html si-local-file:///var/storage/secattach/20260716/26776961.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Edgewise+Therapeutics%2C++++For%3A+Jul+10/26776961.html Thu, 16 Jul 2026 08:01:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Edgewise+Therapeutics%2C++++For%3A+Jul+10/26776961.html si-local-file:///var/storage/secattach/20260716/26776961.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Edgewise+Therapeutics%2C++++For%3A+Jul+10/26776961.html Thu, 16 Jul 2026 08:01:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Edgewise+Therapeutics%2C++++For%3A+Jul+10/26760340.html si-local-file:///var/storage/secattach/20260713/26760340.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Edgewise+Therapeutics%2C++++For%3A+Jul+10/26760340.html Mon, 13 Jul 2026 08:37:00 -0400 EWTX O.34381710 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Edgewise+Therapeutics%2C++++For%3A+Jul+10/26760340.html si-local-file:///var/storage/secattach/20260713/26760340.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Edgewise+Therapeutics%2C++++For%3A+Jul+10/26760340.html Mon, 13 Jul 2026 08:37:00 -0400 EWTX O.34381710 http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html <p>Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group, for $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestone payments, bringing potential total consideration to $2.65 billion.</p> <p>Under the terms of the deal, Servier acquired all rights to sevasemten, including related intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting the muscular dystrophy business received offers to transition to Servier.</p> <p>Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate, http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html Mon, 13 Jul 2026 08:30:55 -0400 A.05786303 A.13459824 A.22194166 EWTX O.00053334 O.00981936 O.34381710 http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html <p>Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group, for $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestone payments, bringing potential total consideration to $2.65 billion.</p> <p>Under the terms of the deal, Servier acquired all rights to sevasemten, including related intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting the muscular dystrophy business received offers to transition to Servier.</p> <p>Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate, http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html Mon, 13 Jul 2026 08:30:55 -0400 A.05786303 A.13459824 A.22194166 EWTX O.00053334 O.00981936 O.34381710 http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html <p>Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group, for $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestone payments, bringing potential total consideration to $2.65 billion.</p> <p>Under the terms of the deal, Servier acquired all rights to sevasemten, including related intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting the muscular dystrophy business received offers to transition to Servier.</p> <p>Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate, http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html Mon, 13 Jul 2026 08:30:55 -0400 A.05786303 A.13459824 A.22194166 EWTX O.00053334 O.00981936 O.34381710 http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html <p>Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group, for $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestone payments, bringing potential total consideration to $2.65 billion.</p> <p>Under the terms of the deal, Servier acquired all rights to sevasemten, including related intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting the muscular dystrophy business received offers to transition to Servier.</p> <p>Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate, http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html Mon, 13 Jul 2026 08:30:55 -0400 A.05786303 A.13459824 A.22194166 EWTX O.00053334 O.00981936 O.34381710 http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html <p>Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group, for $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestone payments, bringing potential total consideration to $2.65 billion.</p> <p>Under the terms of the deal, Servier acquired all rights to sevasemten, including related intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting the muscular dystrophy business received offers to transition to Servier.</p> <p>Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate, http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html Mon, 13 Jul 2026 08:30:55 -0400 A.05786303 A.13459824 A.22194166 EWTX O.00053334 O.00981936 O.34381710 http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html <p>Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group, for $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestone payments, bringing potential total consideration to $2.65 billion.</p> <p>Under the terms of the deal, Servier acquired all rights to sevasemten, including related intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting the muscular dystrophy business received offers to transition to Servier.</p> <p>Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate, http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html Mon, 13 Jul 2026 08:30:55 -0400 A.05786303 A.13459824 A.22194166 EWTX O.00053334 O.00981936 O.34381710 http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html <p>Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international pharmaceutical group, for $1.55 billion in upfront cash and up to $1.1 billion in regulatory and commercial milestone payments, bringing potential total consideration to $2.65 billion.</p> <p>Under the terms of the deal, Servier acquired all rights to sevasemten, including related intellectual property, regulatory filings, and clinical data. Edgewise employees primarily supporting the muscular dystrophy business received offers to transition to Servier.</p> <p>Edgewise said it expects the upfront proceeds, combined with its existing cash, to fully fund development of its lead cardiovascular candidate, http://www.streetinsider.com/Mergers+and+Acquisitions/Edgewise+sells+muscular+dystrophy+drug+to+Servier+for+up+to+%242.65B/26760278.html Mon, 13 Jul 2026 08:30:55 -0400 A.05786303 A.13459824 A.22194166 EWTX O.00053334 O.00981936 O.34381710 http://www.streetinsider.com/Mergers+and+Acquisitions/Servier+buys+Edgewise+muscular+dystrophy+unit+for+up+to+%242.65B/26760273.html <p>Servier, a French pharmaceutical group, has completed its acquisition of the muscular dystrophy business of Edgewise Therapeutics (Nasdaq: EWTX) for up to $2.65 billion, according to a press release from the company.</p> <p>The deal includes an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments. The transaction closed following regulatory clearance and customary closing conditions.</p> <p>The acquisition gives Servier control of sevasemten, an investigational oral drug described as a potential first-in-class fast skeletal myosin inhibitor. The compound is currently being evaluated in a pivotal cohort for Becker muscular dystrophy (BMD) and in a phase 2 http://www.streetinsider.com/Mergers+and+Acquisitions/Servier+buys+Edgewise+muscular+dystrophy+unit+for+up+to+%242.65B/26760273.html Mon, 13 Jul 2026 08:30:42 -0400 A.13459824 EWTX O.00156996 O.34381710